The Patent Finder

Chembridge Corporation

Also on record
Records under this name other than patents Chembridge Corporation holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Showing 1 to 10 of 10 · Back to Chembridge Corporation

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 9,273,055Tyrosine kinase inhibitors
Lapsed on the fee record
Ended Mar 1, 2024 · USPTO record
Lapsed on the fee recordEnded Mar 1, 2024USPTO record
US 9,249,147Tyrosine kinase inhibitors
Lapsed on the fee record
Ended Feb 2, 2024 · USPTO record
Lapsed on the fee recordEnded Feb 2, 2024USPTO record
US 8,063,225Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
Lapsed on the fee record
Ended Nov 22, 2023 · USPTO record
Lapsed on the fee recordEnded Nov 22, 2023USPTO record
US 8,629,147Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
Lapsed on the fee record
Ended Jan 14, 2022 · USPTO record
Lapsed on the fee recordEnded Jan 14, 2022USPTO record
US 9,290,503Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
Lapsed on the fee record
Ended Mar 22, 2020 · USPTO record
Lapsed on the fee recordEnded Mar 22, 2020USPTO record
US 7,915,260Urotensin II receptor antagonists
Formerly held
Lapsed on the fee record
Ended Mar 29, 2019 · USPTO record
Lapsed on the fee recordEnded Mar 29, 2019USPTO record
US 8,822,500Tyrosine kinase inhibitors
Lapsed on the fee record
Ended Sep 2, 2018 · USPTO record
Lapsed on the fee recordEnded Sep 2, 2018USPTO record
US 8,815,906Tyrosine kinase inhibitors
Lapsed on the fee record
Ended Aug 26, 2018 · USPTO record
Lapsed on the fee recordEnded Aug 26, 2018USPTO record
US 8,686,005Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
Lapsed on the fee record
Ended Apr 1, 2018 · USPTO record
Lapsed on the fee recordEnded Apr 1, 2018USPTO record
US 6,872,827Somatostatin analogue compounds
Lapsed on the fee record
Ended Mar 29, 2013 · USPTO record
Lapsed on the fee recordEnded Mar 29, 2013USPTO record
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited